Status:
COMPLETED
Cognitive-Behavioral Therapy and Tai Chi Chih for Patients With Rheumatoid Arthritis
Lead Sponsor:
University of California, Los Angeles
Collaborating Sponsors:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Rheumatoid arthritis (RA) is a chronic illness. Patients with RA often experience significant pain and depression. This study will evaluate two programs designed to improve the symptoms of RA: cogniti...
Detailed Description
Rheumatoid arthritis is a progressive inflammatory illness marked by severe functional declines, significant economic and social costs, and significant psychological distress. Environmental and psycho...
Eligibility Criteria
Inclusion
- Diagnosis of RA as defined by the American College of Rheumatology (ACR) and consistent with revised criteria for RA
- Stable disease-modifying drug regimen for 3 months prior to study entry, with no change in drug dosage for at least 3 months prior to study entry
- Relatively stable disease course for 3 months prior to study entry
- If treated with corticosteroids, must be on a stable dosage for 3 months prior to study entry
- If taking prednisone, must be on a dosage less than or equal to 10 mg/day or equivalent
- Resides in Greater Los Angeles area
Exclusion
- Inactive RA conditions defined as "in remission"
- Experiencing frequent, severe disease flares that require changes in primary disease-modifying regimen
- Serious medical conditions, including: diabetes, congestive heart failure, renal failure requiring specific treatment, cancer (unless cured for period of 5 years or more), unregulated endocrine disorders (including thyroid disorders), chronic uncontrolled infection, or any uncontrolled medical condition that may interfere with the study
- Use of analgesics (e.g., opioids) other than acetaminophen or non-steroidal anti-inflammatory agents prescribed for RA treatment, tramadol (Ultram) or Tylenol with codeine on an as-needed basis, or propoxyphen (Darvocet, Wygesic)
- Use of oxycodone (Percocet), hydrocodone (Vicodin), morphine, or hydromorphone (Dilaudid)
- Use of high levels of methotrexate (greater than 7.5 mg)
- Use of nitrogen mustard, cyclosporine, monoclonal antibodies, or cyclophosphamide within the 6 months prior to study entry
- Serious psychiatric conditions, such as bipolar disorder, psychotic disorders, or organic brain syndromes
- At risk for suicide
- Dependent on canes, walkers, or other assistive devices
- Unable to commit to study schedule/itinerary or unwilling to be assigned to any of the 3 treatment groups
Key Trial Info
Start Date :
February 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2009
Estimated Enrollment :
106 Patients enrolled
Trial Details
Trial ID
NCT00072657
Start Date
February 1 2004
End Date
March 1 2009
Last Update
April 4 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cousins Center for Psychoneuroimmunology, UCLA
Los Angeles, California, United States, 90095